Amicus Therapeutics believes that it has the opportunity to make a move in the rare disease market - competing with companies like Genzyme for Fabry's Disease patients as an example. This year, Amicus' Amigal was able to capture market share during Genzyme's supply problems with its drug Fabrazyme.
Amicus CEO, John Crowley says "It is good for people to have options for the treatment of rare diseases." See Fierce Biotech.
Posted by Bruce Lehr Feb 16th 2011.